RATIONALE: The nonspecific clinical presentation of pulmonary embolism (PE) frequently leads to delay in its diagnosis. OBJECTIVES: This study aimed to assess the impact of delay in presentation on the diagnostic management and clinical outcome of patients with suspected PE. METHODS: In 4,044 consecutive patients with suspected PE, patients presenting more than 7 days from the onset of symptoms were contrasted with those presenting within 7 days as regards the safety of excluding PE on the basis of a clinical decision rule combined with D-dimer testing. Patients were followed for 3 months to assess the rates of recurrent venous thromboembolism and mortality. MEASUREMENTS AND MAIN RESULTS: A delayed presentation (presentation >7 d) was present in 754 (18.6%) of the patients. The failure rate of an unlikely clinical probability and normal D-dimer test was 0.5% (95% confidence interval [CI], 0.01-2.7) for patients with and 0.5% (95% CI, 0.2-1.2) for those without diagnostic delay. D-dimer testing yielded a sensitivity of 99% (95% CI, 96-99%) and 98% (95% CI, 97-99%) in these groups, respectively. Patients with PE with diagnostic delay more frequently had centrally located PE (41% vs. 26%; P < 0.001). The cumulative rates of recurrent venous thromboembolism (4.6% vs. 2.7%; P = 0.14) and mortality (7.6% vs. 6.6%; P = 0.31) were not different for patients with and without delayed presentation. CONCLUSIONS: PE can be safely excluded based on a clinical decision rule and D-dimer testing in patients with a delayed clinical presentation. A delayed presentation for patients who survived acute PE was associated with a more central PE location, although this did not affect the clinical outcome at 3 months.
RATIONALE: The nonspecific clinical presentation of pulmonary embolism (PE) frequently leads to delay in its diagnosis. OBJECTIVES: This study aimed to assess the impact of delay in presentation on the diagnostic management and clinical outcome of patients with suspected PE. METHODS: In 4,044 consecutive patients with suspected PE, patients presenting more than 7 days from the onset of symptoms were contrasted with those presenting within 7 days as regards the safety of excluding PE on the basis of a clinical decision rule combined with D-dimer testing. Patients were followed for 3 months to assess the rates of recurrent venous thromboembolism and mortality. MEASUREMENTS AND MAIN RESULTS: A delayed presentation (presentation >7 d) was present in 754 (18.6%) of the patients. The failure rate of an unlikely clinical probability and normal D-dimer test was 0.5% (95% confidence interval [CI], 0.01-2.7) for patients with and 0.5% (95% CI, 0.2-1.2) for those without diagnostic delay. D-dimer testing yielded a sensitivity of 99% (95% CI, 96-99%) and 98% (95% CI, 97-99%) in these groups, respectively. Patients with PE with diagnostic delay more frequently had centrally located PE (41% vs. 26%; P < 0.001). The cumulative rates of recurrent venous thromboembolism (4.6% vs. 2.7%; P = 0.14) and mortality (7.6% vs. 6.6%; P = 0.31) were not different for patients with and without delayed presentation. CONCLUSIONS: PE can be safely excluded based on a clinical decision rule and D-dimer testing in patients with a delayed clinical presentation. A delayed presentation for patients who survived acute PE was associated with a more central PE location, although this did not affect the clinical outcome at 3 months.
Authors: Srinivas R Banala; Sai-Ching Jim Yeung; Terry W Rice; Cielito C Reyes-Gibby; Carol C Wu; Knox H Todd; W Frank Peacock; Kumar Alagappan Journal: Int J Emerg Med Date: 2017-06-06
Authors: Janneke M T Hendriksen; Marleen Koster-van Ree; Marcus J Morgenstern; Ruud Oudega; Roger E G Schutgens; Karel G M Moons; Geert-Jan Geersing Journal: BMJ Open Date: 2017-03-09 Impact factor: 2.692
Authors: Geert-Jan Geersing; Toshihiko Takada; Frederikus A Klok; Harry R Büller; D Mark Courtney; Yonathan Freund; Javier Galipienzo; Gregoire Le Gal; Waleed Ghanima; Jeffrey A Kline; Menno V Huisman; Karel G M Moons; Arnaud Perrier; Sameer Parpia; Helia Robert-Ebadi; Marc Righini; Pierre-Marie Roy; Maarten van Smeden; Milou A M Stals; Philip S Wells; Kerstin de Wit; Noémie Kraaijpoel; Nick van Es Journal: PLoS Med Date: 2022-01-25 Impact factor: 11.069
Authors: Alex Upfill-Brown; Richard Hwang; Sam Clarkson; Dane Brodke; Sai Devana; Erik Mayer; Benjamin Kelley; Armin Arshi; Christopher Lee Journal: OTA Int Date: 2021-11-03
Authors: Omran Al Dandan; Ali Hassan; Afnan Alnasr; Mohammed Al Gadeeb; Hossain AbuAlola; Sarah Alshahwan; Malak Al Shammari; Alaa Alzaki Journal: Int J Emerg Med Date: 2020-05-11